BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 25741004)

  • 21. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
    Gao Y; Bergman I
    J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus.
    Ahmed M; Puckett S; Lyles DS
    Cancer Gene Ther; 2010 Dec; 17(12):883-92. PubMed ID: 20725101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.
    Galivo F; Diaz RM; Wongthida P; Thompson J; Kottke T; Barber G; Melcher A; Vile R
    Gene Ther; 2010 Feb; 17(2):158-70. PubMed ID: 20016540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity.
    van den Pol AN; Davis JN
    J Virol; 2013 Jan; 87(2):1019-34. PubMed ID: 23135719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
    Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis.
    Muscolini M; Castiello L; Palermo E; Zevini A; Ferrari M; Olagnier D; Hiscott J
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31092575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy.
    Shulak L; Beljanski V; Chiang C; Dutta SM; Van Grevenynghe J; Belgnaoui SM; Nguyên TL; Di Lenardo T; Semmes OJ; Lin R; Hiscott J
    J Virol; 2014 Mar; 88(5):2927-40. PubMed ID: 24371063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
    Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
    Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein.
    Stegelmeier AA; Chan L; Mehrani Y; Petrik JJ; Wootton SK; Bridle B; Karimi K
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
    Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
    Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses.
    Udayakumar TS; Betancourt DM; Ahmad A; Tao W; Totiger TM; Patel M; Marples B; Barber G; Pollack A
    Mol Cancer Res; 2020 Aug; 18(8):1232-1243. PubMed ID: 32366674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.
    Velazquez-Salinas L; Naik S; Pauszek SJ; Peng KW; Russell SJ; Rodriguez LL
    Hum Gene Ther Clin Dev; 2017 Jun; 28(2):108-115. PubMed ID: 28514874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes.
    Wollmann G; Davis JN; Bosenberg MW; van den Pol AN
    J Virol; 2013 Jun; 87(12):6644-59. PubMed ID: 23552414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways.
    Paglino JC; van den Pol AN
    J Virol; 2011 Sep; 85(18):9346-58. PubMed ID: 21734048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
    Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
    Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
    Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
    Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.
    Felt SA; Droby GN; Grdzelishvili VZ
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28566376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.
    Saloura V; Wang LC; Fridlender ZG; Sun J; Cheng G; Kapoor V; Sterman DH; Harty RN; Okumura A; Barber GN; Vile RG; Federspiel MJ; Russell SJ; Litzky L; Albelda SM
    Hum Gene Ther; 2010 Jan; 21(1):51-64. PubMed ID: 19715403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
    Naik S; Nace R; Barber GN; Russell SJ
    Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
    Nelson A; McMullen N; Gebremeskel S; De Antueno R; Mackenzie D; Duncan R; Johnston B
    Breast Cancer Res; 2024 May; 26(1):78. PubMed ID: 38750591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.